Sensus Healthcare wins FDA nod for next-gen SRT-100+ radiation therapy system

Superficial radiation therapy device developer Sensus Healthcare (NSDQ:SRTSU) said today it won FDA 510(k) clearance for its SRT-100+ next-gen superficial radiation therapy system. The newly cleared device includes all the features of the Boca Raton, Fla.-based company’s SRT-100 as well as an expanded energy range, remote diagnostics and operation tracking, a new X-ray tube for extended functionality and an advacned console and system mobility. “We have integrated both clinical and patient feedback to bring to life exciting new elements with the SRT-100+—from live lesion and patient cameras for monitoring during treatment to best-in-class system enhancements for better patient setup and comfort. The sophisticated operation of the SRT-100+ also offers significant benefits to doctors specifically, as it will be integrated with practices’ information technology and management / electronic medical records, as well as provide vital data backup and logging. This represents the technology of the future when it comes to treating NMSC and keloids safely and effectively,” CTO Kal Fishman said in a prepared statement. “The SRT-100+ is truly the next step forward for Sensus’ transformative products that have treated more than 400,000 skin cancer and keloids patients all around the world. This new offering is the culmination of all of our clinical experience and best practices that we have learned from our broad global user base of ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Oncology Regulatory/Compliance Sensus Healthcare LLC Source Type: news

Related Links:

Medical Laser Pioneer and Veteran Entrepreneur Brings Over 30 Years of Experience to Company BOCA RATON, Fla., Feb. 28, 2019 -- (Healthcare Sales &Marketing Network) -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in h... Devices, Oncology, Dermatology, Personnel Sensus Healthcare, superficial radiation therapy, skin cancer, Keloids
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Superficial radiation therapy device developer Sensus Healthcare (NSDQ:SRTSU) today released plans for a global expansion, including new distribution agreements in China, Germany, Mexico, Cuba and Costa Rica. Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids. The Boca Raton, Fla.-based company refers to the technology as superficial radiation therapy, and claims that the tech has been sued to “effectively and safely treat oncological and non-oncological skin conditions.” “Following our new partnersh...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Distribution Oncology Sensus Healthcare LLC Source Type: news
Sensus Healthcare is a medical device company that focuses on providing non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids utilizing superficial radiation technology (SRT). Their proprietary, FDA-cleared SRT technology...
Source: Medgadget - Category: Medical Devices Authors: Tags: Dermatology Exclusive Oncology Source Type: blogs
[Image from unsplash.com]From Hologic’s new product launch to CapsoVision gettting CE Mark approval, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Hologic launches new MyoSure device Hologic announced in a Nov. 1 press release that it has launched its MyoSure Manual Device in the U.S. The device is designed to help doctors resect and remove intrauterine tissue easily in an office setting if used with the MyoSure hysteroscope. 2. IntraFuse wins FDA clearance for FlexThread fibula pin IntraFuse has received FDA 510(k) clearance for its FlexThread Fibula Pin System, ...
Source: Mass Device - Category: Medical Devices Authors: Tags: 510(k) Endoscopic / Arthroscopic Oncology Orthopedics Pain Management Regulatory/Compliance Surgical Ultrasound Women's Health brhmedical CapsoVision Helomics Hologic Inc. IntraFuse MedTech Sensus Healthcare LLC Skyline Med Source Type: news
To develop a novel conformal superficial brachytherapy (CSBT) device as a treatment option for the patient-specific radiation therapy of conditions including superficial lesions, postsurgical positive margins, Dupuytren's contractures, keloid scars, and complex anatomic sites (eyelids, nose, ears, etc.).
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
BOCA RATON, Fla., Aug. 2, 2016 -- (Healthcare Sales &Marketing Network) -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial ra... Devices, Dermatology, Oncology, Personnel Sensus Healthcare, superficial radiation therapy, skin cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Sensus Healthcare (NSDQ:SRTSU) said today it closed its initial public offering, raising $11 million through the sale of 2.3 million units at $5.50 each. The offering included a fully-exercised underwriters option of an additional 300,000 units at the IPO price, Sensus said. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus makes low-energy photon X-ray systems for treating non...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Funding Roundup Initial Public Offering (IPO) Radiosurgery Sensus Healthcare LLC Source Type: news
Sensus Healthcare (NSDQ:SRTSU) priced an $11 million initial public offering yesterday, saying it plans to float 2 million shares at $5.50 apiece starting today. Boca Raton, Fla.-based Sensus said the offering, expected to close June 8, also includes a 300,000-unit over-allotment option for the IPO’s underwriters. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus mak...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Funding Roundup Initial Public Offering (IPO) Radiosurgery Wall Street Beat Sensus Healthcare LLC Source Type: news
Introduction: KV x-ray beams are used in radiotherapy for skin cancer, keloids and IORT. High dose gradients, detector volume and energy response, and also the use of small fields, makes choosing appropriate detectors critical.
Source: Physica Medica: European Journal of Medical Physics - Category: Journals (General) Authors: Source Type: research
This article describes the creation, development and ongoing evaluation of a burn training program, created in conjunction with the Canadian Network for International Surgery, for parts of east Africa. Selecting the best and brightest: A comparison of residency match processes in the United States and CanadaPlastic surgery remains a competitive field, with many candidates applying to a limited number of residency programs in Canada and the United States annually. However, Canadian programs de-emphasize academic measures and use distinctly different criteria that are less objective than their American counterparts. This sur...
Source: Plastic Surgery - Category: Cosmetic Surgery Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Costa Rica Health | Cuba Health | Dermatology | Electronic Medical Records (EMR) | Germany Health | Information Technology | Keloids | Mexico Health | Radiation Therapy | Skin | Skin Cancer